sensorion

Sensorion Appoints Gene Therapy and Rare Disease Expert Nora Yang as Chief Scientific Officer

MONTPELLIER, FRANCE — Sensorion, a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces the appointment of Nora Yang, Ph.D., a leader in gene therapy and rare diseases with extensive leadership experience in industry, academia, and government, as…

Read More
sensorion sens-401 hearing loss aro

Sensorion Presents Promising New Preclinical Data on SENS-401 at ARO 2021

MONTPELLIER, FRANCE – Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces the presentation of three posters at the 2021 Association for Research in Otolaryngology (ARO) Virtual MidWinter Meeting. This includes a poster on the preclinical evidence…

Read More
sensorion sens-401 cisplatin

Sensorion Provides Update on Development of SENS-401 for the Prevention of Hearing Loss

MONTPELLIER, FRANCE — Sensorion, a pioneering clinical stage biotechnology company which specializes in the development of novel therapies to restore, treat and  prevent within the field of hearing loss disorders, announces it plans to initiate a proof-of-concept clinical trial of SENS-401 to treat cisplatin-induced ototoxicity (CIO) in the second half (H2) of 2021. The company…

Read More
sonova invests sensorion

Sonova Acquires 3.7% Stake in Sensorion as the Companies Plan a Collaboration in Hearing Loss

MONTPELLIER, FRANCE — Sensorion, a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces that Sonova Holding AG (headquartered in Switzerland), a leading provider of hearing solutions, will acquire a 3.7% ownership stake in Sensorion by way of subscription…

Read More
sensorion

Sensorion Reports 2020 First Half Results; Financial Position Strengthened with Recent $36.5M Capital Raise

MONTPELLIER, FRANCE – Sensorion, a pioneering clinical stage and gene therapy biotech company specializing in the development of novel therapies to treat,  prevent and restore within the field of hearing loss disorders, announced its interim annual results as of June 30, 2020 alongside its outlook for 2020.  “Sensorion’s landmark gene therapy agreement with Institut Pasteur…

Read More
sensorion

Sensorion Announces Appointment of Five Renowned Experts to its Scientific Advisory Board

MONTPELLIER, FRANCE — Sensorion, a clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, has announced the appointment of five renowned experts to its Scientific Advisory Board (SAB). Sensorion’s SAB is chaired by Professor Christine Petit, MD, PhD, a globally renowned…

Read More
sensorion

Sensorion Appoints Former Ablynx CEO, Dr. Edwin Moses, as Chairman of the Board

MONTPELLIER, FRANCE —  Sensorion, a clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, has announced the appointment of Edwin Moses, former Chief Executive Officer of Ablynx, as Chairman of its Board of Directors.  Edwin brings more than 25 years of…

Read More
sensorion

Sensorion Announces Positive Preliminary Preclinical Data from Gene Therapy Program

MONTPELLIER, FRANCE — Sensorion, a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announced promising new preliminary data in non-human primates from its ongoing gene therapy program targeting the Otoferlin encoding gene (OTOF).  The following results relate to the…

Read More
sensorion

Coronavirus Outbreak Contributes to Delays in Sensorion’s Sudden Hearing Loss Phase II Clinical Trial

MONTPELLIER, FRANCE — Sensorion, a clinical-stage biotech company specializing in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, has announced updated timelines for the ongoing Phase 2 study of SENS-401 to treat Sudden Sensorineural Hearing Loss (SSNHL). Patient recruitment rates from this trial now indicate the…

Read More
sensorion

Gene Therapy Expert, Dr. Géraldine Honnet, Appointed as Sensorion’s New Chief Medical Officer

MONTPELLIER, FRANCE — Sensorion, a clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, has announced the appointment of gene therapy expert Géraldine Honnet MD, as Chief Medical Officer.  Géraldine Honnet is a medical doctor and joins from Généthon, where she…

Read More